journal article·2023-08-14

Codelivery of Que and BCL-2 siRNA with Lipid–Copolymer Hybrid Nanocomplexes for Efficient Tumor Regression

Kangkang Li, Xiaohua Cai, Yong Fan, Meng Jin, Yi Xie, Zhenghui Jing, Xinlong Zang, Yantao Han

Publisher page

Abstract

The efficacy of chemotherapy is often reduced due to the chemotherapy resistance of tumor cells, which is usually caused by abnormal gene overexpression. Herein, multifunctional nanocomplexes (Que/siBCL2@BioMICs) were developed to deliver quercetin (Que) and BCL-2 siRNA (siBCL2) to synergistically inhibit tumor growth. The nanocomplexes were composed of an amphiphilic triblock copolymer of poly(ethylene glycol) methyl ether methacrylate–poly[2-(dimethylamino) ethyl acrylate]–polycaprolactone (PEGMA–PDMAEA–PCL) and 1,2-distearoyl- sn -glycero-3-phosphoethanolamine-poly(ethylene glycol)-biotin (DSPE–PEG–biotin). Que was encapsulated into the cores through hydrophobic interactions, while negatively charged siBCL2 was loaded through electrostatic interactions. The nanocomplexes could effectively facilitate cellular uptake via biotin-mediated active targeting and cytosolic release of cargos by the “proton sponge effect” of PDMAEA. Que/siBCL2@BioMICs achieved enhanced cytotoxicity and anti-metastasis activity due to a synergistic effect of Que and siBCL2 in vitro. More importantly, superior anti-tumor efficacy was observed in orthotopic 4T1 tumor-bearing mice with reduced primary tumor burden and lung metastatic nodules, while no obvious side effects to major organs were observed. In conclusion, the biotin-targeted nanocomplexes with chemotherapeutic and nucleotide agent entrapment provide a promising strategy for efficient triple-negative breast cancer (TNBC) therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Basic Medicine, Qingdao University, Ningxia Road, Qingdao 266071, PR China

Department of Pharmacy, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao 266000, China

Department of Psychiatry, Qingdao Mental Health Center, Qingdao 266032, China

Department of Positron Emission Tomography-Computed Tomography (PET-CT) Center, The Affiliated Hospital of Qingdao University, Qingdao 266000, China

Funding

National Natural Science Foundation of China · Qingdao post-doctoral program

References (68)

Show source-provided references
1. 10.1038/2529210.1038/25292 ↗
2. 10.1038/nature0794310.1038/nature07943 ↗
3. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
4. 10.1002/adma.20210392310.1002/adma.202103923 ↗
5. 10.1186/s12943-017-0683-y10.1186/s12943-017-0683-y ↗
6. 10.1021/acsbiomaterials.1c0124410.1021/acsbiomaterials.1c01244 ↗
7. 10.1016/j.jcis.2020.07.05710.1016/j.jcis.2020.07.057 ↗
8. 10.1021/acsami.0c1766010.1021/acsami.0c17660 ↗
9. 10.1016/j.carbpol.2020.11678110.1016/j.carbpol.2020.116781 ↗
10. 10.1016/j.biomaterials.2019.11924710.1016/j.biomaterials.2019.119247 ↗
11. 10.1016/j.addr.2014.09.01010.1016/j.addr.2014.09.010 ↗
12. 10.1016/j.nantod.2012.06.01310.1016/j.nantod.2012.06.013 ↗
13. 10.1039/c9nj03277k10.1039/c9nj03277k ↗
14. 10.1186/s12951-021-00981-710.1186/s12951-021-00981-7 ↗
15. 10.1002/adfm.20160170310.1002/adfm.201601703 ↗
16. 10.1016/j.biomaterials.2020.11976010.1016/j.biomaterials.2020.119760 ↗
17. 10.1021/ja401350x10.1021/ja401350x ↗
18. 10.1038/nature0734010.1038/nature07340 ↗
19. 10.1038/nrurol.2011.8110.1038/nrurol.2011.81 ↗
20. 10.1158/1535-7163.MCT-08-072210.1158/1535-7163.MCT-08-0722 ↗
21. 10.1158/0008-5472.CAN-09-301210.1158/0008-5472.CAN-09-3012 ↗
22. 10.1093/annonc/mdf19110.1093/annonc/mdf191 ↗
23. 10.1126/science.275.5303.112910.1126/science.275.5303.1129 ↗
24. 10.1038/nm0697-61410.1038/nm0697-614 ↗
25. 10.1016/j.mattod.2014.05.00210.1016/j.mattod.2014.05.002 ↗
26. 10.2217/17435889.3.6.76110.2217/17435889.3.6.761 ↗
27. 10.1158/0008-5472.CAN-04-457010.1158/0008-5472.CAN-04-4570 ↗
28. 10.1023/a:101096061537010.1023/a:1010960615370 ↗
29. 10.1080/10717544.2022.205522510.1080/10717544.2022.2055225 ↗
30. 10.1016/j.aca.2008.10.03810.1016/j.aca.2008.10.038 ↗
31. 10.1016/j.colsurfb.2020.11128410.1016/j.colsurfb.2020.111284 ↗
32. 10.1016/j.ijpharm.2020.11983010.1016/j.ijpharm.2020.119830 ↗
33. 10.1016/j.jconrel.2009.10.00710.1016/j.jconrel.2009.10.007 ↗
34. 10.1002/adma.20190327710.1002/adma.201903277 ↗
35. 10.1016/j.actbio.2018.05.03110.1016/j.actbio.2018.05.031 ↗
36. 10.1016/j.jconrel.2008.06.00410.1016/j.jconrel.2008.06.004 ↗
37. 10.1016/j.biomaterials.2007.05.02510.1016/j.biomaterials.2007.05.025 ↗
38. 10.1529/biophysj.107.12023810.1529/biophysj.107.120238 ↗
39. 10.1039/c5cc03075g10.1039/c5cc03075g ↗
40. 10.1021/acs.biomac.8b0027210.1021/acs.biomac.8b00272 ↗
41. 10.1016/j.ejpb.2016.10.01710.1016/j.ejpb.2016.10.017 ↗
42. 10.1155/2021/705413410.1155/2021/7054134 ↗
43. 10.22088/IJMCM.BUMS.10.1.1110.22088/IJMCM.BUMS.10.1.11 ↗
44. 10.1002/cbdv.20080014110.1002/cbdv.200800141 ↗
45. 10.4149/BLL_2017_02510.4149/BLL_2017_025 ↗
46. 10.1016/s0092-8674(02)00908-x10.1016/s0092-8674(02)00908-x ↗
47. 10.1080/15384101.2019.159872510.1080/15384101.2019.1598725 ↗
48. 10.3390/ijms2101013110.3390/ijms21010131 ↗
49. 10.1016/j.clnesp.2022.01.00410.1016/j.clnesp.2022.01.004 ↗
50. 10.1007/s10495-016-1334-210.1007/s10495-016-1334-2 ↗
51. 10.7150/jca.5208810.7150/jca.52088 ↗
52. 10.1021/cb500259e10.1021/cb500259e ↗
53. 10.1042/BSR2019072010.1042/BSR20190720 ↗
54. 10.1016/j.cbi.2019.01.00810.1016/j.cbi.2019.01.008 ↗
55. 10.1007/s11033-021-06516-510.1007/s11033-021-06516-5 ↗
56. 10.1002/tox.2262310.1002/tox.22623 ↗
57. 10.1038/srep3522310.1038/srep35223 ↗
58. 10.1007/s11010-014-2317-710.1007/s11010-014-2317-7 ↗
59. 10.1159/00037402410.1159/000374024 ↗
60. 10.1021/jf201096v10.1021/jf201096v ↗
61. 10.1155/2020/815764010.1155/2020/8157640 ↗
62. 10.14715/cmb/2018.64.8.110.14715/cmb/2018.64.8.1 ↗
63. 10.3233/CBM-13030510.3233/CBM-130305 ↗
64. 10.18632/oncotarget.1308310.18632/oncotarget.13083 ↗
65. 10.38212/2224-6614.309010.38212/2224-6614.3090 ↗
66. 10.1111/cpr.1229610.1111/cpr.12296 ↗
67. 10.1080/17425247.2016.118248510.1080/17425247.2016.1182485 ↗
68. 10.1021/acsami.7b0511910.1021/acsami.7b05119 ↗